pharmacoeconomics

Topic: pharmacoeconomics
critical assessment of the pharmacoeconomic evaluations of infliximab and adalimumab made in NICE TA187; https://www.nice.org.uk/nicemedia/live/12985/48552/48552.pdf). You should critically evaluate the economic model used and consider whether or not the conclusions made within the recommendations are supported by the economic evaluation provided. This will require some evaluation of the clinical effectiveness of these agents as reported within the technology appraisal. As part of the critical evaluation you should suggest the feasibility, advantages and disadvantages of alternative pharmacoeconomic models that may have theoretically been applied to this particular technology and indication